Knight Therapeutics Inc.
Research Knight Therapeutics Inc. (GUD) on Bullrun: market cap CAD 1.18B, P/E 74.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGUD
- ExchangeTO
- CountryCanada
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCAD
- Market capCAD 1.18B
- P/E74.9
- Financial periodQ2 2026
- RevenueCAD 144.21M
- Net income-CAD 3.36M
- Free cash flowCAD 27.92M
- Gross margin48.3%
Valuation Snapshot
latest market cap is CAD 1.18B; P/E is 74.9.
Peer valuation comparison
Latest P/E is 74.88x versus a Healthcare sector median of 21.8x (243.5% above).
Latest P/E is 74.88x versus a Canada median of 14.95x (400.9% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | CAD 1.18B | 74.9 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CAD.
About Knight Therapeutics Inc.
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy;
ETFs that hold Knight Therapeutics Inc.
US-listed ETFs
Knight Therapeutics Inc. is held by 8 US-listed ETFs, going by the latest portfolios they filed with the SEC, most traded first:
| ETF | Weight | Fee |
|---|---|---|
| Avantis International Equity ETF (AVDE) | <0.01% | 0.23% |
| Dimensional International Core Equity Market ETF (DFAI) | <0.01% | 0.18% |
| Dimensional International Core Equity 2 ETF (DFIC) | <0.01% | 0.22% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
| Dimensional International Small Cap ETF (DFIS) | 0.02% | 0.39% |
| Dimensional International Small Cap Value ETF (DISV) | 0.04% | 0.42% |
| State Street SPDR S&P International Small Cap ETF (GWX) | 0.07% | 0.40% |
| Dimensional International Vector Equity ETF (DXIV) | 0.02% | 0.30% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Knight Therapeutics Inc.'s market cap?
Knight Therapeutics Inc.'s market capitalization is CAD 1.18B.
What is Knight Therapeutics Inc.'s P/E ratio?
Knight Therapeutics Inc.'s price-to-earnings (P/E) ratio is 74.9.
What does Knight Therapeutics Inc. do?
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America.